TXMD earnings analysis
What we found in TXMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
TherapeuticsMD reported $869 thousand of second-quarter license revenue and $164 thousand of net income from continuing operations, while operating expenses increased 2.3% to $1.7 million. Gross margin remained 100.0%, but the revenue decline and expense base continue to constrain operating performance. Cash was $9.2 million, and the filing provided no quantitative forward guidance; management continues to evaluate strategic alternatives. Risk factors were unchanged from the 2025 10-K/A.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- License revenue declined 8.7%
- The filing reports second-quarter license revenue of $869 thousand, down 8.7% year over year from $952 thousand in the prior-year quarter.
- Continuing operations remained profitable
- Net income from continuing operations was $164 thousand for the quarter, versus a loss-oriented operating profile in the prior-year period.
- Higher operating expenses pressured margins
- Operating expenses increased 2.3% to $1.7 million, creating pressure on operating profitability despite $869 thousand of license revenue.
- Cash balance was $9.2 million
- Cash and cash equivalents were $9.2 million at quarter-end, providing liquidity for ongoing operations and strategic evaluation.
- Gross margin remained 100%
- Gross margin was 100.0%, consistent with the company’s license-revenue model and the prior-year quarter.
- Disclosure controls deemed effective
- Management concluded that disclosure controls were effective as of the end of the period, while noting that controls provide reasonable—not absolute—assurance.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependence on licensed-product revenue
- The company depends on licensed-product sales; quarterly license revenue was $869 thousand and declined 8.7% year over year, indicating concentration and revenue-volatility risk.
- Expense base exceeds quarterly revenue
- Operating expenses rose 2.3% to $1.7 million while reported license revenue was $869 thousand, creating continued risk of operating losses and cash consumption.
- Existing risks remain unchanged
- The filing states there have been no material changes to the risk factors since the 2025 10-K/A; therefore, existing risks remain applicable, including uncertainty around the company’s strategic alternatives.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 100.0%
What they said about what is next.
No quantitative forward guidance was provided in the filing; management continues to evaluate strategic alternatives.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- TherapeuticsMD reported Q1 2026 results reflecting a significant increase in revenue to $724,000, up from $393,000 in Q1 2025, indicating a positive trend driven by licensed product sales. The company also achieved a…
- 10-K · March 30, 2026
- TherapeuticsMD has repositioned as a pharmaceutical royalty company (change completed Dec. 30, 2022) and generated materially higher license revenue in 2025 vs. 2024. Revenue rose from $1,761,000 in 2024 to $3,022,000…
- 10-Q · August 12, 2025
- TherapeuticsMD reported Q2 2025 license revenue of $952,000, up from $234,000 in Q2 2024, producing GAAP net income of $551,000 (EPS $0.05) versus a net loss of $(1,090,000) (EPS $(0.09)) in the prior-year quarter.…
- 10-Q · August 12, 2024
- TherapeuticsMD reported Q2 license and service revenue of $234 thousand, down from $437 thousand in Q2 2023 and $313 thousand in Q1 2024, while net loss narrowed to $1,090 thousand (EPS -$0.09) from a $2,414 thousand…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TXMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever